Clinical trials: Acute Myocardial Infarction of Left Ventricle
Cardiogenic Shock
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
Long term prognosis of cardiogenic shock is related to the resolution of haemodynamic failure, associated visceral failure and the recovery of an adequate myocardial function.
- Trial name
- EMPASHOCK (NCT05879276)
- Testing
- Empagliflozin 10 MG
- Where
- 8 sites in France
- Volunteers
- 164 people
- Sponsor
- Central Hospital, Nancy, France
Myocardial Infarction With Non-Obstructive Coronary Artery, Myocarditis Acute
Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA and MINOCA-mimics
This clinical study examines patients presenting with acute myocardial infarction and no significant coronary artery disease on coronary angiography (MINOCA) and patients with MINOCA-mimics with advanced CMR.
- Conditions
- Myocardial Infarction With Non-Obstructive Coronary Artery, Myocarditis Acute, Takotsubo Cardiomyopathy, Spontaneous Coronary Artery Dissection
- Trial name
- COPE-CMR (NCT06323811)
- Testing
- CMR
- Where
- Switzerland
- Volunteers
- 75 people
- Sponsor
- University of Zurich
Myocardial Infarction, Death
BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction
This is a multinational, multicentre, randomised open-label, controlled, parallel-group phase III study. Its aim is to demonstrate that a single intracoronary infusion of autologous bone marrow-derived mononuclear cells is safe…
- Trial name
- BAMI (NCT01569178)
- Testing
- Bone Marrow aspiration and intracoronary reinfusion
- Where
- 33 sites in Belgium, Czechia and 8 more
- Volunteers
- 375 people
- Sponsor
- Queen Mary University of London
Acute Myocardial Infarction
IRIS : Use of Implantable Defibrillator in High-risk Patients Early After Acute Myocardial Infarction
Of the patients who survive hospitalization after an acute myocardial infarction, ca. 10% die of sudden cardiac death in the following 2 years. The prognosis appears not improved by medication with antiarrhythmics (class I/III).
- Trial name
- NCT00157768
- Testing
- Implantable cardioverter defibrillator
- Where
- Netherlands
- Volunteers
- 900 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Myocardial Infarction
Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI
Development of myocardial reparative therapy for the treatment of acute ischemic cardiac disease, based on the intracoronary administration of allogeneic Cardiac Stem Cells (CSCs) to ameliorate myocardial cell death and promote…
- Trial name
- CAREMI (NCT02439398)
- Testing
- Allogeneic human cardiac stem cells (CSCs), Human Serum Albumin-HSA 5%
- Where
- Spain
- Volunteers
- 55 people
- Sponsor
- Coretherapix
Acute Myocardial Infarction
Bone Marrow Derived Adult Stem Cells for Acute Anterior Myocardial Infarction
Study hypothesis : The purpose of this study is to determine whether Intracoronary infusion of autologous bone marrow derived progenitor cells to patients undergoing primary angioplasty for acute anterior myocardial infarction…
- Trial name
- REGEN-AMI (NCT00765453)
- Where
- 5 sites in Denmark, Switzerland and 1 more
- Volunteers
- 100 people
- Sponsor
- Barts & The London NHS Trust
Myocardial Infarction
Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction
The primary objective of this study is to establish the effects of a single bolus of EPO, administered within three hours after a primary PCI for a first acute myocardial infarction, on left ventricular function.
- Trial name
- HEBEIII (NCT00449488)
- Testing
- epoetin alfa
- Where
- Netherlands
- Volunteers
- 529 people
- Sponsor
- University Medical Center Groningen
STEMI, Acute Myocardial Infarction
Resistance STEMI Study
In acute myocardial infarction, early restoration of blood flow to the jeopardized myocardium is of paramount importance to limit infarct size and to improve long term outcome.
- Trial name
- NCT03439150
- Testing
- Absolute flow and resistance measurement
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Myocardial Infarction
Effect of Dapagliflozin on LV Remodeling Post AMI
The overall hypothesis of the study is that Dapagliflozin will reduce left ventricular remodeling in patients who have had a myocardial infarction.
- Trial name
- NCT04783870
- Testing
- Dapagliflozin
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Instituto Mexicano del Seguro Social
Myocardial Infarction
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
Study OPL-0301-201 is intended to generate efficacy and safety data of OPL-0301 in participants with post-myocardial infarction (MI) left ventricular dysfunction (LVD)
- Trial name
- RESTORE (NCT05327855)
- Testing
- OPL-0301 Dose 1, OPL-0301 Dose 2
- Sponsor
- Valo Health, Inc.
Myocardial Infarction
Bone Marrow-Derived Stem Cell Transfer in Acute Myocardial Infarctions
The benefit of reperfusion therapies for ST-elevation acute myocardial infarction (STEMI) is limited by postinfarction left ventricular (LV) dysfunction.The purpose of this study is to determine whether intracoronary transfer of…
- Trial name
- NCT00264316
- Testing
- bone marrow-derived stem cell transfer
- Where
- Belgium
- Volunteers
- 68 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Acute Coronary Syndrome
The Contemporary Role of Beta Blockers in Patients With Acute Myocardial Infarction
The use of beta blockers after acute myocardial infarction is a core component of drug therapy, but evidence is primarily derived from patients who did not receive reperfusion therapy and secondary prophylaxis.In contemporary…
- Trial name
- NCT04564365
- Testing
- beta-blocker
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Medical University
Left Ventricular Remodeling, Acute Myocardial Infarction
Danlou Tablets to Prevent Left Ventricular Remodeling
Danlou tablets are Chinese patent medicine which has been approved in China for the treatment of ischemic heart disease, but the evidence supporting its efficacy on cardiac remodeling remains unclear.
- Trial name
- NCT02675322
- Testing
- Danlou Tablets
- Volunteers
- 82 people
- Sponsor
- shuai Mao
Acute Myocardial Infarction
Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction
Early reperfusion strategies in tandem with remarkable advances in drugs and devices for treating myocardial infarction (MI) have contributed to a reduction in early mortality, but cardiovascular disease remains the leading cause…
- Trial name
- SEED-MSC (NCT01392105)
- Testing
- Mesenchymal stem cell, Control group
- Where
- 3 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yonsei University
Acute Coronary Syndrome, Cardiogenic Shock
Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock
A Clinical Events Committee (CEC) will include Cardiac Surgery Professor and chief of cardiac surgery Rose Kelly MD, Professor of Medicine Ganesh Raveendran MD at the University of Minnesota who is the direction of Interventional…
- Trial name
- NCT05426083
- Testing
- Physiological Assessment
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Minnesota
Congestive Heart Failure, Mitral Regurgitation
Speckle Tracking Imaging and Realtime 3 Dimensional Echocardiograhy to Study LV Function and Remodeling After Acute Myocardial Infarction (AMI)
Left ventricular (LV) remodeling after acute myocardial infarction (AMI) has been well described in previous studies. However, there is a paucity of data on the incidence of and risk factors for LV remodeling in modern clinical…
- Trial name
- NCT00745680
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Acute Myocardial Infarction
Strain-Encoded Magnetic Resonance Imaging in Acute Myocardial Infarction
The aim of the study was therefore to evaluate whether myocardial deformation imaging performed by SENC allows for quantification of regional left ventricular function and is related to transmurality states of infarcted tissue in…
- Trial name
- 137-2005 (NCT00752713)
- Testing
- cardiac MRI
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Thrombus of Left Ventricle
Cohort of Patients With Left Ventricular Thrombus: Management and Outcomes in the Direct Oral Anticoagulants Era
The investigators' primary objective is to assess whether a difference in the occurrence of bleeding events exist between patients with LVT treated with DOACs as compared to those treated with VKAs.
- Trial name
- LV-Thrombus (NCT05028777)
- Where
- Switzerland
- Volunteers
- 550 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Ischemic Heart Disease, Myocardial Infarction
Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT to Predict Left Ventricular Remodelling in Patients Reperfused in the Acute Phase of MI
Left myocardial infarction (MI), has a negative impact of long term morbidity and mortality. Even in patients treated successfully by angioplasty in the acute phase of infarct, the remodelling is observed in approximately 30% of…
- Trial name
- NCT00487812
- Testing
- Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Clermont-Ferrand
Myocardial Infarction, Acute, Heart Failure, Left Sided
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
This is a Phase 2, multicenter, randomized, parallel, 3-arm, placebo-controlled study to assess efficacy and safety of CDR132L in patients with reduced Left Ventricular Ejection Fraction (LVEF) (≤ 45%) after myocardial infarction…
- Trial name
- HF-REVERT (NCT05350969)
- Testing
- CDR132L
- Where
- 49 sites in Czechia, Germany and 6 more
- Volunteers
- 294 people
- Sponsor
- Cardior Pharmaceuticals GmbH